Welcome to Scribd, the world's digital library. Read, publish, and share books and documents. See more
Download
Standard view
Full view
of .
Look up keyword
Like this
2Activity
0 of .
Results for:
No results containing your search query
P. 1
9550

9550

Ratings: (0)|Views: 74 |Likes:
Published by Chris Nash

More info:

Published by: Chris Nash on Jul 26, 2008
Copyright:Attribution Non-commercial

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as PDF, TXT or read online from Scribd
See more
See less

06/26/2012

pdf

text

original

 
 Effectiveness and Costs of OsteoporosisScreening and Hormone Replacement Therapy, Vol. II: Evidence on Benefits, Risks, and Costs
August 1995
OTA-BP-H-144GPO stock #052-003-01424-6
 
M
enopause typically occurs in women around age 50. Accompany-ing this life event is a decline in estrogen levels and an increase inthe rate of decline in women’s bone density. This rapid bone lossincreases women’s subsequent risk of developing osteoporosis, a
disease characterized by low bone density and increased bone fragility.
Among the most serious consequences of osteoporosis is fracture of the hip,
which may result in substantial morbidity, prolonged hospitalization, anddeath. Estrogen can prevent bone loss after menopause by replacing the
body’s own estrogen. Given the serious consequences of osteoporosis,
some osteoporosis experts have recommended that women have their bonemineral density measured at the time of menopause and those with the low-
est bone mineral density be offered
hormone replacement therapy,
com-
prising estrogen given alone or in combination with the hormone progestin.This background paper,
 Effectiveness and Costs of Osteoporosis Screen-ing and Hormone Replacement Therapy,
assesses the medical benefits andcosts of both screening and hormone replacement therapy. It is divided into
two volumes. The first volume,
Cost-Effectiveness Analysis,
presents the
results of a model that estimates the cost per year of life gained from osteo-
porosis screening and hormone replacement therapy in postmenopausalwomen. The second volume,
 Evidence on Benefits, Risks, and Costs,
pro-
vides the basis for the assumptions about the costs and effects of screening
and hormonal replacement therapy used in the cost-effectiveness model.
This background paper is one of three documents resulting from OTA’sassessment of policy issues in the prevention and treatment of osteoporosis.This assessment was requested by the Senate Special Committee on Aging,
Senator Charles Grassley and Senator John Glenn, and the House SelectCommittee on Aging, Representative Olympia J. Snowe, Representative
Benjamin A. Gilman, and former Representatives Brian J. Donnelly,
Thomas J. Downey, and Patricia F. Saiki. Two background papers in this se-ries have been issued, both in July 1994:
Public Information about Osteopo-
rosis: What’s’ Available, What’s Needed?,
and
 Hip Fracture Outcomes inPeople Age Fifty and Over.
ROGER C. HERDMAN
Director
F
oreword
iii
 
P
reface
T
his volume, “Evidence on Benefits, Risks, and Costs of Hormonal
Replacement Therapy,” is a companion to the volume “Cost-Effec-
tiveness Analysis” of the OTA background paper “Effectivenessand Costs of Osteoporosis Screening and Hormone ReplacementTherapy.” This volume reviews evidence on the impact of hormonal re-placement therapy (HRT) on bone density, fractures, breast cancer, endo-metrial cancer, gallbladder disease, and heart disease that underlies the as-sumptions used in OTA’s cost-effectiveness analysis. This volume alsoincludes information about hormonal replacement therapy dosage regi-
mens; reviews the relationship between bone mineral density and hip frac-ture; and summarizes the costs of bone mineral density screening, interven-tion, and diseases affected by HRT.
This volume is organized as a series of appendices. Several appendices
review HRT’s impacts on disease, including:
s
Appendix B:“Evidence on Hormonal Replacement Therapy and
Fractures,”
s
Appendix F:“Evidence on Hormonal Replacement Therapy and
Breast Cancer,”
s
Appendix G: “Evidence on HRT and Endometrial Cancer, ”
s
Appendix H:
“Evidence on HRT and Gallbladder Disease,” and
s
Appendix I:
“Evidence on HRT and Coronary Heart Disease.”Appendix D,“Summary of Hip Fracture Prediction Methods,” details
the method for predicting the number of hip fractures used in OTA’s cost-ef-
fectiveness analysis. The appendix describes the specific parameter as-
sumptions and sources of data regarding the longitudinal distribution of bone mass in menopausal women from ages 50 to 90. The appendix also
describes the specific parameter assumptions and sources of data regarding
the short-term relationship of bone mass to fractures at each age.Appendix E,“Hormonal Replacement Therapy Regimens,” describes
the types of estrogens and progestins used for hormonal replacement thera-
py, their doses, and their administration. The appendix also describes theimpact of hormonal replacement therapy on menopausal symptoms, andadverse effects of HRT, such as bleeding and premenstrual-tension-like
symptoms. The appendix also describes the impact of these various dosageregimens on compliance with HRT.
Appendix J,
“Methods for Estimating Costs,” provides the basis for
OTA’s assumptions concerning the costs of bone mineral density measure-
ment, hormone replacement therapy, heart disease, hip fractures, gallblad-
der disease, endometrial cancer, and breast cancer.
v

You're Reading a Free Preview

Download
scribd
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->